Trillium Announces Voting Results From the Annual and Special Meeting of Shareholders
July 06, 2020 07:00 ET
|
Trillium Therapeutics Inc.
CAMBRIDGE, Mass., July 06, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) (the “Corporation”), a clinical stage immuno-oncology company developing innovative therapies for...
Trillium Therapeutics Provides Update on the Phase I Dose Escalation Study of Its CD47 Blocker TTI-622 at the ASCO20 Virtual Scientific Program
May 29, 2020 08:00 ET
|
Trillium Therapeutics Inc.
Dosing has progressed through first five cohorts up to 4 mg/kg dose levelStrong safety profile, with no dose-limiting toxicities observedMonotherapy activity (1 CR and 1 PR) observed in DLBCL...
Trillium Therapeutics Reports First Quarter 2020 Financial and Operating Results
May 15, 2020 17:00 ET
|
Trillium Therapeutics Inc.
CAMBRIDGE, Mass., May 15, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...
Trillium Therapeutics to Present Data on CD47 Blocker TTI-622 in Advanced Relapsed or Refractory Lymphoma at the ASCO20 Virtual Scientific Program
May 13, 2020 07:00 ET
|
Trillium Therapeutics Inc.
CAMBRIDGE, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...
Trillium Therapeutics Announces “At-The-Market” Equity Program
May 06, 2020 07:00 ET
|
Trillium Therapeutics Inc.
CAMBRIDGE, Mass., May 06, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...
TRILLIUM THERAPEUTICS PROVIDES BUSINESS UPDATE IN RESPONSE TO THE COVID-19 PANDEMIC
April 08, 2020 07:00 ET
|
Trillium Therapeutics Inc.
First patients in the 1.4 mg/kg cohort of TTI-621 and the 8.0 mg/kg cohort of TTI-622 clinical studies have been dosed. Going forward, expect a slow-down or potentially a pause in enrollment of new...
Trillium Therapeutics Reports Annual Financial and Operating Results
March 10, 2020 07:00 ET
|
Trillium Therapeutics Inc.
CAMBRIDGE, Mass., March 10, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of...
Trillium Therapeutics Responds to Market Activity
February 28, 2020 12:30 ET
|
Trillium Therapeutics Inc.
CAMBRIDGE, Mass., Feb. 28, 2020 (GLOBE NEWSWIRE) -- At the request of IIROC ("Investment Industry Regulatory Organization of Canada"), Trillium Therapeutics Inc. (the “Company”) (NASDAQ/TSX: TRIL)...
Trillium Therapeutics Announces Changes to Its Board of Directors
February 07, 2020 07:00 ET
|
Trillium Therapeutics Inc.
Paul Walker of New Enterprise Associates is appointed to the Board of Directors CAMBRIDGE, Mass., Feb. 07, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”)...
Trillium Closes US$117 Million Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares
January 29, 2020 07:00 ET
|
Trillium Therapeutics Inc.
CAMBRIDGE, Mass., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...